G703135-5 RTMP's copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/40 — A1

(11) International Publication Number: **WO 96/23496**

(43) International Publication Date: 8 August 1996 (08.08.96)

(21) International Application Number: PCT/IB96/00082

(22) International Filing Date: 29 January 1996 (29.01.96)

(30) Priority Data:
381,535 — 1 February 1995 (01.02.95) — US
95303853.6 — 6 June 1995 (06.06.95) — EP
(34) Countries for which the regional or international application was filed: — GB et al.

(60) Parent Application or Grant
(63) Related by Continuation
US — 381,535 (CIP)
Filed on — 1 February 1995 (01.02.95)

(71) Applicant *(for all designated States except US)*: NEURIM PHARMACEUTICALS (1991) LTD. [IL/IL]; 8 Hanechoshet Street, 69710 Tel Aviv (IL).

(71) Applicant *(for GB only)*: DAVIS, Stanley, Joseph [GB/IL]; Even Shmuel 59/3, Ramot Bet, 97230 Jerusalem (IL).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: ZISAPEL, Nava [IL/IL]; 23 Kissufim Street, Tel Aviv (IL).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF MELATONIN FOR TREATING PATIENTS SUFFERING FROM DRUG ADDICTION

(57) Abstract

Melatonin is used in the manufacture of a medicament for treating a multidrug addict, or a patient who has symptoms of having become dependent on, tolerant of, or addicted to a benzodiazepine drug, or for treating a patient who has been clinically diagnosed as having a condition susceptible to alleviation by administration of a benzodiazepine drug, while simultaneously preventing the occurrence in the patient of symptoms of dependence on, tolerance of, or addiction to said benzodiazepine drug. The invention further relates to a pharmaceutical formulation for the above-stated purposes, which comprises at least one diluent, carrier or adjuvant and as active ingredients a benzodiazepine drug and melatonin.